T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments.

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• T-cell-based therapies, initially approved for lymphoid malignancies, are expanding into other cancers.
• Two anti-B cell maturation antigen (BCMA) CAR T-cell therapies are now approved for relapsed/refractory multiple myeloma, demonstrating significant efficacy in pre-treated patients.

Purpose of the Study:

• To review clinical data on T-cell-based therapies for multiple myeloma.
• To discuss the management of unique adverse events associated with these therapies.
• To highlight ongoing research in both clinical and preclinical settings for T-cell therapies in multiple myeloma.

Main Methods:

• Review of clinical trial data and preclinical studies on T-cell-based therapies for multiple myeloma.
• Analysis of adverse event profiles, focusing on cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• Exploration of alternative T-cell-based strategies, including T Cell Receptor (TCR) engineered T-cells and adoptive T-cell transfers.

Main Results:

• Anti-BCMA CAR T-cell therapies have shown excellent efficacy in relapsed and refractory multiple myeloma.
• Unique toxicities, including CRS and ICANS, require specialized management strategies.
• Alternative T-cell therapies like TCR T-cells and Vγ9 Vδ2 T-cells are under investigation for potential to overcome treatment resistance.

Conclusions:

• T-cell-based therapies, particularly CAR T-cells, represent a significant advancement in multiple myeloma treatment.
• Optimizing CAR T-cell engineering, cell selection, and treatment sequencing is crucial for further improvement.
• Ongoing research into novel T-cell strategies and toxicity management is essential for advancing multiple myeloma care.